IN: Integrated Disease Surveillance Project

Abstract*

The development objective of the Integrated Disease Surveillance Project is to improve the information available to government health services, and private health care providers, on a set of high-priority diseases, and risk factors, with a view to improving the grassroots responses to such diseases, and risk factors. The project four components will: 1) establish and operate a central-level disease surveillance unit, under the Ministry of Health and... Show More

Development Objective

To support the Government of India (GOI) to strengthen the integrated disease surveillance system for epidemic-prone diseases by (i) enhancing central level monitoring and coordination functions, and (ii) improving state/district surveillance and response capacity with emphasis on selected (nine) states. Additionally, the project will support GOI efforts to timely prepare for, detect and respond to influenza outbreaks in humans and animals.

Key Details

Project Details

Project ID
P073651
Status
Closed
Team Leader
Somil Nagpal
Borrower 2
N/A

Country
India
Disclosure Date
July 9, 2001
Approval Date
(as of board presentation)
July 8, 2004
Effective Date
October 28, 2004

Total Project Cost 1
US$ 92.00 million
Implementing Agency
N/A
Region
South Asia
Fiscal Year 3
2005

Commitment Amount
US$ 34.05 million
Environmental Category
B
Environmental and Social Risk
Not Applicable
Closing Date
March 31, 2012

Last Stage Reached
BANK APPROVED
Last Update Date
January 15, 2013

Notes
1. Total project cost includes funding from World Bank and non-bank sources in US$ millions. Active and Closed projects show current commitments. Proposed (pipeline) and dropped projects show the forecast amount. The commitment amount for projects in the pipeline is indicative and may be modified during the project preparation.
2. Borrower refers to the Borrower of a Loan or Recipient of a Grant.
3. ”Fiscal Year” is the fiscal year in which the project was approved (or dropped if the status is dropped). The World Bank's fiscal year is from July 1 - June 30. For example, a fiscal year of 1996 corresponds to July 1, 1995 - June 30, 1996.

Sectors

Themes

FY17 - Human Development and Gender

FY17 - Disease Control28%
- FY17 - Non-communicable diseases28%
FY17 - Health Systems and Policies28%
- FY17 - Health System Strengthening28%

FY17 - Public Sector Management

FY17 - Public Administration14%
- FY17 - Municipal Institution Building14%

Project Map

Interactive Map

Finances

Financing Plan (US$ Millions)

Financier	Commitments
Borrower/Recipient	32.00
IDA Credit	34.05

Total Project Financing (US$ Millions)

Product Line	IBRD/IDA
IBRD Commitment	N/A
IDA Commitment	34.05
IBRD + IDA Commitment	34.05

Lending Instrument
Grant Amount	N/A
Total Project Cost**	92.00

Summary Status of World Bank Financing (US$ Millions) as of July 31, 2025

No data available.

Detailed Financial Activity as of July 31, 2025

Download:

Period	Financier	Transaction Type	Amount (US$)
Jul 1, 2020	IDA-39520	Int Charges	1,333.39
Jul 1, 2020	IDA-39520	Int Charges	1,333.39
Jan 1, 2020	IDA-39520	Int Charges	291.38
Jan 1, 2020	IDA-39520	Int Charges	291.38
Jan 1, 2020	IDA-39520	Loan Repay	594,024.40
Jan 1, 2020	IDA-39520	Int Charges	63,261.15
Jan 1, 2020	IDA-39520	Int Charges	63,261.15
Jul 1, 2021	IDA-39520	Loan Repay	305,839.88
Jul 1, 2021	IDA-39520	Int Charges	61,932.58
Jul 1, 2021	IDA-39520	Int Charges	61,932.58
Jul 1, 2021	IDA-39520	Int Charges	7,404.88
Jul 1, 2021	IDA-39520	Int Charges	7,404.88
Jan 1, 2021	IDA-39520	Int Charges	56,313.48
Jan 1, 2021	IDA-39520	Int Charges	56,313.48
Jan 1, 2021	IDA-39520	Int Charges	2,125.35
Jan 1, 2021	IDA-39520	Int Charges	2,125.35
Jan 1, 2021	IDA-39520	Loan Repay	309,349.47
Jan 1, 2022	IDA-39520	Loan Repay	3,177.57
Jan 1, 2022	IDA-39520	Loan Repay	297,434.40
Jan 1, 2022	IDA-39520	Int Charges	59,746.65
Jan 1, 2022	IDA-39520	Int Charges	59,746.65
Jul 1, 2022	IDA-39520	Int Charges	55,700.10
Jul 1, 2022	IDA-39520	Loan Repay	2,891.43
Jul 1, 2022	IDA-39520	Int Charges	55,700.10
Jul 1, 2022	IDA-39520	Loan Repay	568,391.44
Jul 1, 2023	IDA-39520	Int Charges	21,191.79
Jul 1, 2023	IDA-39520	Int Charges	21,191.79
Jul 1, 2023	IDA-39520	Loan Repay	571,360.20
Jul 1, 2023	IDA-39520	Int Charges	51,422.39
Jul 1, 2023	IDA-39520	Int Charges	51,422.39
Jan 1, 2023	IDA-39520	Loan Repay	564,897.25
Jan 1, 2023	IDA-39520	Int Charges	32,391.93
Jan 1, 2023	IDA-39520	Int Charges	32,391.93
Jan 1, 2023	IDA-39520	Loan Repay	6,793.66
Jul 8, 2004	IDA-39520	Loan Commitment	68,000,000.00
Jul 1, 2024	IDA-39520	Int Charges	45,053.32
Jul 1, 2024	IDA-39520	Int Charges	45,053.32
Jul 1, 2024	IDA-39520	Int Charges	15,096.11
Jul 1, 2024	IDA-39520	Int Charges	15,096.11
Jul 1, 2024	IDA-39520	Loan Repay	1,131,078.90
Jan 1, 2024	IDA-39520	Loan Repay	8,521.32
Jan 1, 2024	IDA-39520	Loan Repay	567,998.00
Jan 1, 2024	IDA-39520	Int Charges	34,335.59
Jan 1, 2024	IDA-39520	Int Charges	34,335.59
Jul 1, 2014	IDA-39520	Int Charges	99,770.37
Jul 1, 2014	IDA-39520	Int Charges	99,770.37
Jul 1, 2014	IDA-39520	Int Charges	534.47
Jul 1, 2014	IDA-39520	Int Charges	534.47
Jan 1, 2014	IDA-39520	Int Charges	97,873.84
Jan 1, 2014	IDA-39520	Int Charges	97,873.84
Jan 1, 2014	IDA-39520	Int Charges	825.62
Jan 1, 2014	IDA-39520	Int Charges	825.62
Jul 1, 2013	IDA-39520	Int Charges	95,570.16
Jul 1, 2013	IDA-39520	Int Charges	95,570.16
Jul 1, 2013	IDA-39520	Int Charges	1,173.86
Jul 1, 2013	IDA-39520	Int Charges	1,173.86
Jul 1, 2013	IDA-39520	Int Charges	-6,012.69
Jul 1, 2013	IDA-39520	Int Charges	6,012.69
Jan 1, 2016	IDA-39520	Loan Repay	2,507.91
Jan 1, 2016	IDA-39520	Int Charges	82,593.72
Jan 1, 2016	IDA-39520	Int Charges	82,593.72
Jan 1, 2016	IDA-39520	Loan Repay	592,762.20
Jul 1, 2015	IDA-39520	Loan Repay	587,792.44
Jul 1, 2015	IDA-39520	Int Charges	85,831.71
Jul 1, 2015	IDA-39520	Int Charges	85,831.71
Jul 1, 2015	IDA-39520	Loan Repay	14,535.55
Jan 1, 2015	IDA-39520	Int Charges	91,021.20
Jan 1, 2015	IDA-39520	Int Charges	91,021.20
Jan 1, 2015	IDA-39520	Loan Repay	2,249.31
Jan 1, 2015	IDA-39520	Loan Repay	620,118.20
Jul 1, 2014	IDA-39520	Loan Repay	665,135.60
Jul 1, 2017	IDA-39520	Loan Repay	16,216.25
Jul 1, 2017	IDA-39520	Loan Repay	581,485.25
Jul 1, 2017	IDA-39520	Int Charges	65,575.61
Jul 1, 2017	IDA-39520	Int Charges	65,575.61
Jul 1, 2016	IDA-39520	Loan Repay	594,215.25
Jul 1, 2016	IDA-39520	Int Charges	80,954.74
Jul 1, 2016	IDA-39520	Int Charges	80,954.74
Jul 1, 2016	IDA-39520	Loan Repay	5,449.40
Jan 1, 2017	IDA-39520	Loan Repay	567,066.60
Jan 1, 2017	IDA-39520	Int Charges	75,795.05
Jan 1, 2017	IDA-39520	Int Charges	75,795.05
Jan 1, 2017	IDA-39520	Loan Repay	10,419.22
Jul 1, 2018	IDA-39520	Loan Repay	98,980.15
Jul 1, 2018	IDA-39520	Loan Repay	505,242.25
Jul 1, 2018	IDA-39520	Int Charges	72,506.69
Jul 1, 2018	IDA-39520	Int Charges	72,506.69
Jul 1, 2018	IDA-39520	Int Charges	9,216.72
Jul 1, 2018	IDA-39520	Int Charges	9,216.72
Jan 1, 2018	IDA-39520	Int Charges	10,881.45
Jan 1, 2018	IDA-39520	Int Charges	10,881.45
Jan 1, 2018	IDA-39520	Loan Repay	611,765.70
Jan 1, 2018	IDA-39520	Int Charges	27,098.27
Jan 1, 2018	IDA-39520	Int Charges	27,098.27
Jan 1, 2018	IDA-39520	Int Charges	39,275.92
Jan 1, 2018	IDA-39520	Int Charges	39,275.92
Jul 1, 2019	IDA-39520	Int Charges	66,789.49
Jul 1, 2019	IDA-39520	Int Charges	66,789.49
Jul 1, 2019	IDA-39520	Int Charges	2,225.37
Jul 1, 2019	IDA-39520	Int Charges	2,225.37
Jul 1, 2019	IDA-39520	Loan Repay	596,283.90
Jan 1, 2019	IDA-39520	Loan Repay	13,684.09
Jan 1, 2019	IDA-39520	Loan Repay	583,759.60
Jan 1, 2019	IDA-39520	Int Charges	67,223.15
Jan 1, 2019	IDA-39520	Int Charges	67,223.15
Jul 1, 2020	IDA-39520	Loan Repay	295,775.00
Jul 1, 2020	IDA-39520	Int Charges	60,080.66
Jul 1, 2020	IDA-39520	Int Charges	60,080.66

Footnotes

Ratings

IMPLEMENTATION RATINGS

Name	Review	Date
Progress towards achievement of PDO	Moderately Satisfactory	2012-04-10
Monitoring and Evaluation	Moderately Satisfactory	2012-04-10
Overall Implementation Progress (IP)	Moderately Satisfactory	2012-04-10
Procurement	Moderately Satisfactory	2012-04-10
Project Management	Moderately Satisfactory	2012-04-10
Financial Management	Moderately Satisfactory	2012-04-10
Counterpart Funding	Satisfactory	2012-04-10

COMPLETION RATINGS

INDICATOR	IMPLEMENTATION COMPLETION & RESULTS REPORT: 11-29-2012
Outcomes	Moderately Satisfactory
Risk to Development Outcome	Modest
Bank Performance	Moderately Satisfactory
Borrower Performance	Moderately Satisfactory
Government Performance	Substantial
Implementing Agency	Moderately Unsatisfactory

INDEPENDENT EVALUATION RATINGS

INDICATOR	ICR REVIEW: 02-11-2013	PROJECT PERFORMANCE ASSESSMENT REPORT:
Outcome Rating	Moderately Satisfactory	N/a
Risk To Development Outcome	Moderate	N/a
Bank Performance	Moderately Satisfactory	N/a
Borrower Performance	Moderately Satisfactory	N/a
Government Performance	Moderately Satisfactory	N/a
Implementing Agency	Moderately Satisfactory	N/a
Icr Quality	Satisfactory	N/a
M&e Quality	Modest	N/a

Results Framework

PROJECT DEVELOPMENT OBJECTIVE INDICATORS

INDICATOR		BASELINE	CURRENT	TARGET

% of districts providing surveillance reports timely and consistently in 9 priority states	Value	25.00	57.00	70.00
	Date	March 30, 2010	December 31, 2011	March 31, 2012
	Comment	25% of priority state districts report timely and consistently on 'P' forms from Primary Health Centres. Data for all other 4 subindicators (% of districts reporting timely and consistently for 'P' forms from hospitals with Outpatient and Inpatientsurveillance;% lab confirmation for outbreaks; % of district priority labs reporting routinely and % of labs from referral networkreporting routinely) is not available	On an average 98% of districts report on 'P' and 'L' forms. % of districts providing timely and consistent 'P' forms from PrimaryHealth Centers is 57%, from hospitals with outpatient and inpatient surveillance is 48%. %of lab confirmed outbreaks is 37%; 94% ofdistrict public health labs report routinely; 100% of labs from the referral network report are reporting.

% of responses to disease specific outbreaks assessed to be adequate as measured by 3 essential criteria in 9 priority states	Value	45.00	74.00	75.00
	Date	March 30, 2010	December 31, 2011	March 31, 2012
	Comment	Over all 45% of outbreaks (based on first criterion). Range is : TN & KA-66, UK, WB, MH=50%, AP-20% Rajasthan 10% PB=0	Utilization of lab facilities with appropriate human samples (i.e., the second criterion in the above PDO indicator, afteradjusting the denominator by excluding disease conditions where lab confirmation based on human samples is not technicallyfeasible) improved to 74%.

Improved diagnostic capacity for H5N1 and H1N1	Value	9.00	14.00	18.00
	Date	March 30, 2010	February 29, 2012	March 31, 2012
	Comment	For Human Health: 7 labs Animal Health: 2 Biosafety Level III (BSL3)	For Human Health: 11/12 labs functional (91%)Animal Health: 3/6 BSLIII labs are functional (50%)	Human Health: 12 labsAnimal Health: 6 BSL3 labs

No: of functional diagnostic laboratories for human influenza established	Value	7.00	12.00	12.00
	Date	September 30, 2009	February 29, 2012	March 31, 2012
	Comment	Of twelve units, seven are functional	All 12 established but only 11 of 12 HH AI labs functional. NEIGRIMS, Shillong is the only lab which is yet to test any humansamples for either H5N1 or H1N1.

No: of functional BSL3 laboratories for animal influenza established	Value	2.00	3.00	6.00
	Date	September 30, 2009	February 29, 2012	March 31, 2012
	Comment	of six labs, only two are functional	No change, same as previous ISR

INTERMEDIATE RESULTS INDICATORS

INDICATOR		BASELINE	CURRENT	TARGET

% of districts with IT network for on portal data entry, videoconferencing and inter-voice connection between states & have access to toll free 1075	Value	25.00	95.00	80.00
	Date	September 30, 2009	February 29, 2012	March 31, 2012
	Comment	Portal =40% VCF =50% TFA= 25%	- % of districts with Portal data entry = 95 %- % of districts utilizing VC facility = 95%- % of districts having Toll freeno.1075 connectivity = 95%	80% for all 3 facilities throughout the year

% of major hospitals enrolled, doing IP , OP & Lab Surveillance , and sharing P & L forms	Value	20.00	72.00	50.00
	Date	March 30, 2010	February 29, 2012	March 31, 2012
	Comment	less then 20%	average 70% for P form (hospital) and average 74% for L form (lab)

Number of meetings between health officials and animal husbandry officials	Value	0.00	2.00	2.00
	Date	March 30, 2010	December 31, 2011	March 31, 2012
	Comment		Monthly (in high risk states)/bi-monthly meetings are called in at-risk states by the Additional Chief Secretary and thePrincipalHealth Secretary inviting all other line department secretaries	at least once every six months

% of epidemiologists, microbiologists and entomologists in position	Value	40.00	58.27	90.00
	Date	March 30, 2010	February 29, 2012	March 31, 2012
	Comment		126/231 sanctioned project positions of epidemiologists are filled (plus 35 additional epidemiologists from regular serviceavailable to IDSP for Gujarat & Punjab), 22/26 sanctioned microbiologists positions filled; and 7/9 sanctioned entomologistpositions. 100%of posted epidemiologists are trained, 95.5% of microbiologists are trained and 100% of the posted entomologists aretrained.

Number of CSU supervision missions in each of the nine states (per year)	Value	2.00	4.00	4.00
	Date	March 30, 2010	February 29, 2012	March 31, 2012
	Comment		AP- 3; GJ -5; KA –5; MH -2; PJ– 5; RJ– 4; TN – 1; UK – 4; WB – 5 between January 2011 and February 2012

Induction training completed; epidemiologists/microbiologists and entomologists in position	Value	40.00	98.50	90.00
	Date	September 30, 2009	February 29, 2012	March 31, 2012
	Comment		100% of postedepidemiologists are trained,95.5% of microbiologists aretrained and 100% of the postedentomologists are trained.

Health personnel receiving training	Value	0.00	191433.00	0.00
	Date	March 29, 2010	February 29, 2012	March 31, 2012
	Comment		126 epidemiologists trained; 21 microbiologists trained; 9 entomologists trained; 1033 master trainers trained in nine prioritystates and 1599 in non-priority states; 222 personnel trained in FETP from priority states and 293 in non priority states;induction training completed for 89 epidemiologists, 11 entomologists and microbiologists in non-priority states; 26869 medicalofficers and hospital doctors trained; 11440 lab technicians trained; 30410 pharmacists and nurses trained and 119311 healthworkers trained across the country.	All identified personnel under the project should be trained.